Tuning the Endocytosis Mechanism of Zr-Based Metal-Organic Frameworks through Linker Functionalization

被引：53

作者：

Orellana-Tavra, Claudia ^{[1
]}

Haddad, Salame ^{[1
]}

Marshall, Ross J. ^{[2
]}

Lazaro, Isabel Abanades ^{[2
]}

Boix, Gerard ^{[3
,4
]}

Imaz, Inhar ^{[3
,4
]}

Maspoch, Daniel ^{[3
,4
,5
]}

Forgan, Ross S. ^{[2
]}

Fairen-Jimenez, David ^{[1
]}

机构：

[1] Univ Cambridge, AAML, Dept Chem Engn & Biotechnol, Philippa Fawcett Dr, Cambridge CB3 0AS, England

[2] Univ Glasgow, WestCHEM Sch Chem, Joseph Black Bldg,Univ Ave, Glasgow G12 8QQ, Lanark, Scotland

[3] CSIC, Catalan Inst Nanosci & Nanotechnol ICN2, Campus UAB, Barcelona 08193, Spain

[4] Barcelona Inst Sci & Technol, Campus UAB, Barcelona 08193, Spain

[5] ICREA, Pg Lluis Co 23, Barcelona 08010, Spain

来源：

ACS APPLIED MATERIALS & INTERFACES | 2017年 / 9卷 / 41期

基金：

英国工程与自然科学研究理事会; 欧洲研究理事会;

关键词：

metal-organic frameworks; metabolic pathways; drug delivery; endocytosis; DRUG-DELIVERY; CELLULAR UPTAKE; SURFACE-CHARGE; NANOPARTICLES; UIO-66; CAVEOLAE; PATHWAY; CELLS; SIMIAN-VIRUS-40; INTERNALIZATION;

D O I：

10.1021/acsami.7b07342

中图分类号：

TB3 [工程材料学];

学科分类号：

0805 ; 080502 ;

摘要：

A critical bottleneck for the use of metal-organic frameworks (MOFs) as drug delivery systems has been allowing them to reach their intracellular targets without being degraded in the acidic environment of the lysosomes. Cells take up particles by endocytosis through multiple biochemical pathways, and the fate of these particles depends on these routes of entry. Here, we show the effect of functional group incorporation into a series of Zr-based MOFs on their endocytosis mechanisms, allowing us to design an efficient drug delivery system. In particular, naphthalene-2,6-dicarboxylic acid and 4,4 ' biphenyldicarboxylic acid ligands promote entry through the caveolin-pathway, allowing the particles to avoid lysosomal degradation and be delivered into the cytosol and enhancing their therapeutic activity when loaded with drugs.

引用

页码：35516 / 35525

页数：10

共 61 条

[11] Nanoparticle therapeutics: an emerging treatment modality for cancer [J].